Novartis Reports Positive Phase III Results for First-in-Class Complement Therapy Iptacopan in IgA Nephropathy, Aims for Accelerated FDA Approval-VCBeat

On October 2, Novartis announced positive key results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study at the 9th month. The specific complement B factor inhibitor Iptacopan showed superiority over placebo in reducing proteinuria (protein in urine) and provided clinically meaningful and highly statistically significant reduction in proteinuria for patients with IgA nephropathy (a complement-mediated disease) on top of supportive care. In this study, the safety profile of iptacopan (200mg, twice daily) was consistent with previously reported data.Novartis Plans to Act on Interim Data in 2024Seeking from the FDAAccelerated Approval.

The study will continue in a double-blind manner, assessing iptacopan's ability to slow IgAN progression by measuring the slope of estimated glomerular filtration rate (eGFR) over 24 months (the primary endpoint at the end of the study), with key results expected in 2025.

It is estimated that approximately 25 people per million are newly diagnosed with IgAN worldwide each year. Up to 30% of IgAN patients with persistent high levels of proteinuria (≥1g/day) may progress to kidney failure within 10 years. There is a clinical need for effective targeted therapies for IgAN to slow or prevent disease progression to kidney failure. While current supportive therapies help, none address the key pathogenic step in IgAN progression — the activation of the complement system.。

Iptacopan was discovered and developed by Novartis to treat IgAN and other complement-mediated diseases by inhibiting Factor B, a protease essential for the alternative complement pathway.

The marketing application for iptacopan in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) is currently under review by regulatory authorities. In addition,iptacopanCurrently, pivotal studies are being conducted for various complement-mediated diseases (CMD), including renal diseases such as C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), membranous nephropathy (MN), lupus nephritis (LN), as well as immune thrombocytopenic purpura (ITP) and cold agglutinin disease (CAD).

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank You for Your Support! We Look Forward to Your Feedback.

Scan the QR code to provide valuable suggestions